Viridian Therapeutics Inc... (VRDN)
NASDAQ: VRDN
· Real-Time Price · USD
13.98
0.06 (0.43%)
At close: Jun 02, 2025, 3:59 PM
13.50
-3.47%
After-hours: Jun 02, 2025, 07:41 PM EDT
0.43% (1D)
| Bid | 10.5 |
| Market Cap | 1.14B |
| Revenue (ttm) | 302K |
| Net Income (ttm) | -308.32M |
| EPS (ttm) | -3.35 |
| PE Ratio (ttm) | -4.17 |
| Forward PE | -3.67 |
| Analyst | Buy |
| Ask | 16.5 |
| Volume | 622,702 |
| Avg. Volume (20D) | 896,385 |
| Open | 14.16 |
| Previous Close | 13.92 |
| Day's Range | 13.80 - 14.59 |
| 52-Week Range | 9.90 - 27.20 |
| Beta | 0.46 |
About VRDN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VRDN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VRDN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
+7.8%
Viridian Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
5 months ago
+20.67%
Viridian Therapeutics shares are trading higher after the company announced Phase 3 results for its thyroid eye disease treatment trial.
1 month ago · businesswire.com
Viridian Therapeutics Appoints Jeff Ajer to its Board of DirectorsWALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...